Approval · Notice of Compliance 36255 · 2025
EDARBI: Notice of Compliance 36255
Issued October 24, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36255
- Date
- October 24, 2025
- Company
- Bausch Health, Canada Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information. Product Monograph reformatted to the Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EDARBI | Not yet assigned | — |
Medicinal ingredients
- AZILSARTAN MEDOXOMIL POTASSIUM 40 MG per TAB
- AZILSARTAN MEDOXOMIL POTASSIUM 80 MG per TAB